Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Peripheral DES

This article was originally published in The Gray Sheet

Executive Summary

Edwards will focus development of peripheral drug-eluting stents on "vessels where we think we can excel," CEO Michael Mussallem reports during Feb. 3 earnings call. "For example, we think we can do quite well in the SFA," or superficial femoral artery, he says. Edwards has several internal peripheral DES programs, including a research alliance with San Diego-based Happy Valley Medical, developer of the anti-proliferative drug Ceracor (C6-ceramide). HVM is also the "sister company" of stent developer Reva Medical. Meanwhile, Boston Scientific and J&J/Cordis will soon turn their attention to renal drug-eluting stents, Mussallem predicts. "The first target [for] the coronary players...will be the renals. That's a natural target for interventional cardiologists and a natural place for them to be effective"...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT019722

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel